Making Immune “Cold” Tumors Hot

Making_Cold_Tumor_Hot
Share

A main goal of current research and clinical trials is to expand the number of patients that benefit from immune checkpoint inhibitors. Thus, it is perhaps not surprising that combination therapies are the future for these immunotherapies in treating cancer. There are many clinical trials that combine an immunotherapy with conventional chemotherapy (drugs that kill … Read moreMaking Immune “Cold” Tumors Hot

Share

Immunotherapy Antagonists and Agonists

immunotherapy_agonists_antagonists
Share

Some cancer immunotherapy drugs turn off a signaling pathway; others turn on a signaling pathway (1). FDA-approved immunotherapy drugs that target the PD-L1/PD-1 or CTLA-4/B-7 immune checkpoints function as antagonists to block immune signaling pathways. Investigational immunotherapy drugs that target GITRL/GITR function as agonists to activate an immune signaling pathway. Investigational drugs that target OX40L/OX40 … Read moreImmunotherapy Antagonists and Agonists

Share

Understanding Immune Checkpoint Pathways to Improve Patient Response

Cells_of_the_immune_system
Share

Better understanding of the molecular mechanisms that control the adaptive immune system will lead to better immunotherapies for cancer patients or patients with other diseases related to inappropriate immune responses. Two of the processes that inhibit T cell function are called immune checkpoint pathways. New research reveals that these pathways involve many cells of the … Read moreUnderstanding Immune Checkpoint Pathways to Improve Patient Response

Share